Healio
Healio
March 23, 2016
1 min read
Save

Study: Individualized ranibizumab regimen improves visual acuity in patients with CRVO

Individualized dosing of ranibizumab guided by stabilization criteria significantly improved best corrected visual acuity in patients with macular edema secondary to central retinal vein occlusion, a study found.

The prospective, single-arm CRYSTAL study included 357 patients with macular edema secondary to CRVO; 333 patients were evaluated after the first 12 months of the study.

Mean baseline BCVA was 53 letters, and mean duration of CRVO was 8.9 months.

Patients received monthly injections of Lucentis 0.5 mg (ranibizumab, Genentech) until visual acuity was stable for 3 consecutive months. Ranibizumab was then injected as needed if there was a loss of visual acuity due to disease progression. The mean number of injections over the 12 months was 8.1.

At 12 months, the main outcome measures were mean change from baseline BCVA and safety. An exploratory analysis evaluated the presence of macular ischemia.

Ranibizumab yielded a statistically significant mean gain in BCVA from baseline of 12.3 letters (P < .0001).

BCVA improved 10 letters or more in 227 patients (63.8%), 15 letters or more in 175 patients (49.2%) and 30 letters or more in 32 patients (9%).

At 12 months, mean gains in BCVA were 11.6 letters in patients with macular ischemia and 12.1 letters in those without macular ischemia.

Patients who had CRVO for less than 3 months had a BCVA gain of 13.4 letters compared with 11.1 letters for CRVO between 3 months and 9 months, and 10.9 letters for CRVO for 9 months or more.

“The safety findings were consistent with those reported in previous ranibizumab studies in patients with CRVO,” the study authors said. – by Matt Hasson

Disclosure: Larsen reports he is a lecturer for and his hospital receives financial support from Novartis, Allergan, Alcon and Roche. See the study for all other authors’ relevant financial disclosures.

Sources/Disclosures

Collapse
Source:

Larsen M, et al. Ophthalmology. 2016;doi:1016/j.ophtha.2016.01.011.